Hutchmed's HMPL-A251 Becomes First Antibody-Targeted Therapy Conjugate to Enter Clinical Development
核心洞察
Hutchmed's HMPL-A251 (搜索) represents the first antibody-targeted therapy conjugate (ATTC) to enter clinical development, targeting HER2 (搜索) with a PI3K (搜索)/PIKK (搜索) inhibitor payload instead of traditional cytotoxic agents.
The Phase I/IIa trial will recruit 147 patients across 11 sites in the USA and China, with preclinical data showing superior or comparable efficacy to Enhertu in multiple tumor models.
Hutchmed plans to advance two additional ATTC candidates into clinical development within the next year, with HMPL-A580 (搜索) expected in the first half of 2026 and HMPL-A830 (搜索) in the second half.
Hutchmed has achieved a significant milestone in oncology drug development with HMPL-A251 (搜索), the first antibody-targeted therapy conjugate (ATTC) to enter clinical testing. The Phase I/IIa study (NCT07228247) is planned to begin by the end of this month, marking a potential paradigm shift in how targeted cancer (搜索) therapies are designed and delivered.
Novel ATTC Platform Technology
HMPL-A251 (搜索) represents a departure from traditional antibody-drug conjugates (ADCs) by utilizing a PI3K (搜索)/PIKK (搜索) inhibitor as its payload rather than cytotoxic agents. The molecule comprises a highly selective and potent PI3K/PIKK inhibitor conjugated to a humanized anti-HER2 (搜索) IgG1 antibody via a cleavable linker. This first-in-class design is intended to enhance targeted delivery directly to tumor cells while maximizing therapeutic benefit and minimizing systemic exposure.
The ATTC platform combines monoclonal antibodies with small-molecule inhibitor payloads, addressing growing safety concerns associated with cytotoxic ADC payloads while opening possibilities for increased efficacy through multiple specific targeting mechanisms.
Promising Preclinical Results
Preclinical data presented at the recent Triple meeting demonstrated that HMPL-A251 (搜索) achieved superior or comparable efficacy to Enhertu, AstraZeneca and Daiichi (搜索)'s blockbuster HER2 (搜索) ADC, across multiple tumor models. These results suggest the ATTC approach could rival well-established ADCs while potentially offering improved safety profiles.
Clinical Trial Design and Timeline
The Phase I/IIa trial will recruit 147 patients with advanced HER2 (搜索)-expressing solid tumors (搜索) at 11 sites across the USA and China. The oncology community is expected to closely monitor progress throughout 2026 as this novel therapeutic approach undergoes clinical validation.
Expanding ATTC Pipeline
Hutchmed has signaled that HMPL-A251 (搜索) represents only the beginning of its ATTC platform development. The company plans to advance two additional ATTC candidates with undisclosed targets into clinical development over the next year. HMPL-A580 (搜索) is slated for clinical entry in the first half of 2026, followed by HMPL-A830 (搜索) in the second half.
Competitive Landscape
While Hutchmed leads in clinical development, other companies are exploring similar approaches. Accutar Biotechnology (搜索) unveiled preclinical data at AACR for a degrader-based antibody conjugate using its proprietary PI3K𝛼 degrader, AC4847 (搜索), though this program remains in IND-enabling studies.
The advancement of HMPL-A251 (搜索) into clinical testing represents a significant step forward in addressing the limitations of current ADC technologies while potentially opening new avenues for targeted cancer (搜索) therapy development.